FIELD: biochemistry.
SUBSTANCE: group of inventions relates to multivalent and multispecific binding proteins and an application thereof. Binding protein contains three polypeptide chains: the first polypeptide chain contains, from the amino terminus to the carboxy terminus, (i) VLA-CL-VHB-CH1-Fc, where CL is fused directly to VHB, or (ii) VHB-CH1-VLA-CL-Fc, where CH1 is fused directly to VLA, and wherein there are no inserted linkers between the variable domains and constant domains; the second polypeptide chain contains, from the amino terminus to the carboxy terminus, VHA-CH1, wherein there are no inserted linkers between VHA and CH1; the third polypeptide chain contains, from the amino terminus to the carboxy terminus, VLB-CL, wherein there are no inserted linkers between VLB and CL. Two of said first polypeptide chains, two of said second polypeptide chains, and two of said third polypeptide chains are therein capable of associating forming a tetravalent binding protein with double specificity containing six polypeptide chains containing four Fab functional binding fragments. Said binding protein binds both epitope or antigen A and epitope or antigen B. A and B therein constitute different epitopes of the same antigen or different antigens.
EFFECT: binding proteins can be used for treating or preventing acute and chronic inflammatory diseases and disorders, autoimmune diseases, malignant tumours, and other diseases and disorders; proposed structure provides sufficient flexibility and corresponding dimensional parameters for double binding in the absence of a peptide spacer between 2 Fab-binding regions.
32 cl, 7 dwg, 16 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
IMMUNOGLOBULIN WITH TANDEM FAB- FRAGMENTS AND ITS APPLICATION OPTIONS | 2017 |
|
RU2767329C2 |
PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
CRYOPRESERVED CELLS ARE NATURAL KILLERS PRELOADED WITH ANTIBODY CONSTRUCTION | 2019 |
|
RU2819927C2 |
MULTIVALENT PD-L1-BINDING COMPOUNDS FOR TREATING MALIGNANT NEOPLASMS | 2020 |
|
RU2816646C2 |
PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING CROSSOVER FORMAT WITH DOUBLE VARIABLE DOMAIN (CODV) FOR TREATING INFECTION CAUSED BY HIV | 2020 |
|
RU2820164C2 |
TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
INDUCIABLE BINDING PROTEINS AND THEIR USE | 2017 |
|
RU2800034C2 |
FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
Authors
Dates
2022-03-28—Published
2014-12-24—Filed